These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 31412090)

  • 1. National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.
    Kitten AK; Kamath M; Ryan L; Reveles KR
    PLoS One; 2019; 14(8):e0221174. PubMed ID: 31412090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.
    Riad J; Abdelmalek F; Ivers N; Tadrous M
    PLoS One; 2024; 19(8):e0307451. PubMed ID: 39146274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Affecting Prescribing of Type 2 Diabetes Medications in Older Adults within an Integrated Healthcare System.
    Lussier ME; Gionfriddo MR; Graham JH; Wright EA
    J Gen Intern Med; 2024 Feb; 39(2):195-200. PubMed ID: 37783983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults.
    Pilla SJ; Segal JB; Alexander GC; Boyd CM; Maruthur NM
    J Am Geriatr Soc; 2019 May; 67(5):1066-1073. PubMed ID: 30703251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-identified prescriber tendencies in sodium-glucose cotransporter-2 inhibitor outpatient prescribing.
    Thompson K; Bowers BL; Evans AM
    J Am Pharm Assoc (2003); 2024; 64(3):102068. PubMed ID: 38492740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015.
    Bustillos H; Leer K; Kitten A; Reveles KR
    PLoS One; 2018; 13(11):e0208461. PubMed ID: 30500865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study.
    Csatordai M; Benkő R; Matuz M; Engi Z; Csupor D; Lengyel C; Doró P
    Diabetol Metab Syndr; 2024 Apr; 16(1):88. PubMed ID: 38658983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of second-generation antidiabetic medication among a nationally representative sample.
    Truong B; Li Y; Zheng J; Qian J
    Am J Manag Care; 2023 Oct; 29(10):e307-e316. PubMed ID: 37870552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprint of: Self-identified prescriber tendencies in sodium-glucose cotransporter-2 inhibitor outpatient prescribing.
    Thompson K; Bowers BL; Evans AM
    J Am Pharm Assoc (2003); 2024 Aug; ():102177. PubMed ID: 39127942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Computer-aided prescribing: from utopia to reality].
    Suárez-Varela Ubeda J; Beltrán Calvo C; Molina López T; Navarro Marín P
    Aten Primaria; 2005 May; 35(9):451-6. PubMed ID: 15919017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Nuances Surrounding Insulin Prescribing.
    McKee AM; Yancey AM; Zhang RM; McGill JB
    Clin Diabetes; 2023; 41(3):411-419. PubMed ID: 37456092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction to "Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time".
    Diabetes Obes Metab; 2024 Jul; 26(7):3000. PubMed ID: 38639059
    [No Abstract]   [Full Text] [Related]  

  • 13. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study.
    Yaseen A; Lahiri SW
    Clin Diabetes; 2023; 41(4):490-501. PubMed ID: 37849520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
    Li C; Guo S; Huo J; Gao Y; Yan Y; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():987081. PubMed ID: 36277697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Friedreich's Ataxia related Diabetes: Epidemiology and management practices.
    Tamaroff J; DeDio A; Wade K; Wells M; Park C; Leavens K; Rummey C; Kelly A; Lynch DR; McCormack SE
    Diabetes Res Clin Pract; 2022 Apr; 186():109828. PubMed ID: 35301072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probable Tamsulosin-Induced Hyperglycemia: A Case Study.
    Nigro SC; Nolan R; Boemio N
    Clin Diabetes; 2022 Jan; 40(1):113-115. PubMed ID: 35221482
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents.
    Zullo AR; Duprey MS; Smith RJ; Gutman R; Berry SD; Munshi MN; Dore DD
    Diabetes Obes Metab; 2022 Feb; 24(2):247-256. PubMed ID: 34647409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV.
    Strojek K; Pandey AS; Dell V; Sisson M; Wang S; Huyck S; Liu J; Gantz I
    Diabetes Ther; 2021 Apr; 12(4):1175-1192. PubMed ID: 33694093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
    John M; Kalra S; Nair T
    Indian Heart J; 2020; 72(4):312-315. PubMed ID: 32861392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.